Comprehensive analysis pinpoints CCNA2 as a prognostic and immunological biomarker in non-small cell lung cancer
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Cyclin-A2 (CCNA2) is highly expressed in non-small cell lung cancer (NSCLC), correlating with disease progression. This study suggests CCNA2 could be a valuable biomarker for NSCLC diagnosis and prognosis.
Area Of Science
- Oncology
- Molecular Biology
- Genomics
Background
- Lung cancer remains a significant global health challenge with suboptimal survival rates despite advanced therapies.
- The role of Cyclin-A2 (CCNA2) in non-small cell lung cancer (NSCLC) tumorigenesis is not well-defined.
- CCNA2 is known to be upregulated in various cancer types, suggesting a potential role in cancer development.
Purpose Of The Study
- To investigate the expression, prognostic value, and biological function of CCNA2 in NSCLC.
- To determine if CCNA2 can serve as a diagnostic or prognostic biomarker for NSCLC.
- To explore the correlation between CCNA2 expression and immune cell infiltration in NSCLC.
Main Methods
- Analysis of three Gene Expression Omnibus (GEO) microarray datasets to identify differentially expressed genes in NSCLC.
- Construction of a protein-protein interaction (PPI) network to identify hub genes, including CCNA2.
- Validation of CCNA2 expression and prognostic significance using GEPIA, Kaplan-Meier plotter, Human Protein Atlas, UALCAN, qRT-PCR, and immunohistochemistry (IHC).
- Loss-of-function assays and exploration of immune infiltration and single-cell sequencing data.
Main Results
- CCNA2 was found to be significantly upregulated in NSCLC tissues compared to normal tissues.
- High CCNA2 expression correlated with advanced pathological stages and lymph node metastasis.
- CCNA2 demonstrated high diagnostic accuracy, indicated by a significant area under the curve (AUC).
- CCNA2 expression was associated with increased immune cell infiltration, particularly in Tprolif cells.
Conclusions
- CCNA2 is upregulated in NSCLC and its expression is significantly correlated with key clinicopathological characteristics.
- CCNA2 holds promise as a potential biomarker for both diagnosis and prognosis in NSCLC patients.
- Further research into CCNA2's role in immune modulation within the tumor microenvironment is warranted.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
